10-K: Tenax Therapeutics Outlines Capital Structure and Strategic Priorities in 10-K Filing

Tenax Therapeutics' 10-K filing details its capital structure, recent reverse stock splits, and strategic focus on advancing its levosimendan program.

Summary

• Tenax Therapeutics is authorized to issue 400,000,000 shares of common stock and 10,000,000 shares of preferred stock.
• The company effected a 1-for-20 reverse stock split on January 4, 2023, and a 1-for-80 reverse stock split on January 2, 2024.
• These reverse stock splits did not change the number of authorized shares or the par value of the stock, but did proportionately adjust stock options and warrants.
• As of December 31, 2023, there were 210 shares of Series A Preferred Stock outstanding, convertible into 1 share of Common Stock.
• The company is prioritizing its LEVEL trial for oral levosimendan (TNX-103) over its imatinib program.
• The LEVEL trial is a Phase 3 study for pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
• The company has suspended plans to launch an imatinib Phase 3 trial.
• Tenax has taken steps to reduce monthly operating expenses and conserve cash.
• The company has received FDA input on the oral levosimendan protocol and clinical development program.
• The company has initiated sites for the LEVEL trial and commenced enrolling patients in early 2024.
• Additional funding will be needed to complete the LEVEL trial, including its open-label extension phase.
• The company has been granted patents for the use of IV and oral levosimendan in patients with PH-HFpEF.
• A new patent is expected in early 2024 covering all therapeutic doses of all three formulations of levosimendan in PH-HFpEF patients.
• The company is exploring strategic alternatives, including capital raises, a sale of the company, merger, or licensing agreements.
• The company's ability to continue as a going concern depends on its ability to raise additional capital.

Sentiment

Score: 4

Explanation: The document highlights significant financial challenges and the need for additional capital, which is concerning. However, the company is actively pursuing strategic options and has made progress in its clinical programs, which provides some hope.

Positives

• The company has received FDA input on its levosimendan clinical development program.
• The company has initiated sites for the LEVEL trial and commenced enrolling patients.
• The company has been granted patents for the use of levosimendan in PH-HFpEF.
• The company has taken steps to reduce monthly operating expenses and conserve cash.
• The company has a library of ongoing and completed trials and research projects from its licensor, Orion.

Negatives

• The company has incurred losses since its inception and expects to continue to incur losses.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company needs substantial additional capital to complete its clinical trials and commercialize its products.
• The company has suspended plans to launch an imatinib Phase 3 trial.
• The company is dependent on third-party manufacturers and CROs.
• The company has limited marketing capabilities and no sales organization.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company's ongoing exploration of strategic alternatives may not result in completed transactions.
• Failure to maintain compliance with Nasdaq's continued listing requirements could result in delisting.
• The company's operating results are expected to fluctuate on a quarterly and annual basis.
• The company is limited in the number of products it can simultaneously pursue.
• The company's success depends on the success of a small number of product opportunities.
• The company is subject to extensive government regulation, which is expensive and time-consuming.
• The company may not receive all of the anticipated market exclusivity benefits of imatinib's orphan drug designation.
• The company is subject to uncertainty relating to healthcare reform measures and reimbursement policies.
• The company is subject to product liability lawsuits.
• The company's business and operations would suffer in the event of computer system failures or cyber-attacks.
• The company depends on third parties to formulate and manufacture its products.
• The company has no marketing capabilities and no sales organization.
• The company's share price has been volatile and may continue to be volatile.
• Anti-takeover provisions in the company's charter documents and under Delaware law could make an acquisition more difficult.
• The company has not paid cash dividends in the past and does not expect to pay dividends in the future.
• The company's ability to use its net operating loss carryforwards may be subject to certain limitations.

Future Outlook

The company expects to continue to incur losses and will need substantial additional capital to complete its clinical trials and commercialize its products. The company is exploring strategic alternatives to secure additional funding.

Management Comments

• Management has implemented certain cost-cutting measures.
• Management is actively exploring a diverse range of strategic options to help drive stockholder value.

Industry Context

The pharmaceutical and biotechnology industries are intensely competitive, with many companies engaged in similar activities. Tenax is focused on developing treatments for cardiovascular and pulmonary diseases, particularly in areas with unmet medical needs.

Comparison to Industry Standards

• The company's focus on levosimendan for PH-HFpEF is novel, as no therapies are currently approved for this condition.
• The company's development of imatinib for PAH is in competition with other companies developing new therapies for this disease, including some that may also be disease-modifying.
• The company's approach to imatinib development is to use a modified-release oral formulation to reduce gastric intolerance, while other companies are developing an inhaled route of administration.
• The company's reliance on third-party manufacturers and CROs is common in the biotechnology industry.

Management Changes

Legal Proceedings

• The company is subject to litigation in the normal course of business, none of which management believes will have a material adverse effect on the consolidated financial statements.

Related Party Transactions

• On May 17, 2022, the company entered into a securities purchase agreement with then-affiliate Armistice Capital, LLC, pursuant to which the company agreed to sell and issue to the investor 6,623 units in a private placement at a purchase price of $1,240 per unit.

Stakeholder Impact

• Shareholders face the risk of significant dilution if the company raises additional capital through equity offerings.
• Employees may be affected by cost-cutting measures and potential changes in the company's strategic direction.
• Customers (potential patients) may benefit from the development of new treatments for PH-HFpEF and PAH.
• Suppliers and creditors may be affected by the company's financial challenges and potential strategic changes.

Next Steps

• The company will continue to initiate sites and enroll patients in the LEVEL trial.
• The company will complete efficacy and safety analyses of levosimendan versus placebo at the end of the randomized treatment phase of the LEVEL trial.
• The company will continue to explore strategic alternatives, including capital raises, a sale of the company, merger, or licensing agreements.

Key Dates

Keywords

levosimendan, imatinib, pulmonary hypertension, PH-HFpEF, clinical trials, reverse stock split, capital raise, FDA approval, strategic alternatives, orphan drug designation